Novel loci for Alzheimer’s disease identified by a genome-wide association study in Ashkenazi Jews

Author(s): Li, D; Farrell, JJ; Mez, J; Martin, ER; Bush, WS; Ruiz, A; Boada, M; de Rojas, I; Mayeux, R; Haines, JL; Vance, MAP; Wang, L; Schellenberg, GD; Lunetta, KL; Farrer, LA;
Year: 2023;  
Journal: Alzheimer's & Dementia: The Journal of the Alzheimer's Association;  
Volume: 19;  
Issue: 12;  

INTRODUCTION: Most Alzheimer’s disease (AD) loci have been discovered in individuals with European ancestry (EA).
METHODS: We applied principal component analysis using Gaussian mixture models and an Ashkenazi Jewish (AJ) reference genome-wide association study (GWAS) data set to identify Ashkenazi Jews ascertained in GWAS (n = 42,682), whole genome sequencing (WGS, n = 16,815), and whole exome sequencing (WES, n = 20,504) data sets. The association of AD was tested genome wide (GW) in the GWAS and WGS data sets and exome wide (EW) in all three data sets (EW). Gene-based analyses were performed using aggregated rare variants.
RESULTS: In addition to apolipoprotein E (APOE), GW analyses (1355 cases and 1661 controls) revealed associations with TREM2 R47H (p = 9.66 × 10-9 ), rs541586606 near RAB3B (p = 5.01 × 10-8 ), and rs760573036 between SPOCK3 and ANXA10 (p = 6.32 × 10-8 ). In EW analyses (1504 cases and 2047 controls), study-wide significant association was observed with rs1003710 near SMAP2 (p = 1.91 × 10-7 ). A significant gene-based association was identified with GIPR (p = 7.34 × 10-7 ).
DISCUSSION: Our results highlight the efficacy of founder populations for AD genetic studies.